GlobeNewswire (Feb 5, 2013)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
275 people get SOMX articles and Market Currents by email alert.
Get email alerts on SOMX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (Dec 17, 2012)
-
GlobeNewswire (Dec 11, 2012)
-
GlobeNewswire (Oct 31, 2012)
-
GlobeNewswire (Oct 22, 2012)
-
GlobeNewswire (Aug 27, 2012)
-
Merck's Next-Gen Sleep Disorder Drug - A Blockbuster?Rx Stocks • Mon, Aug 27, 2012
-
GlobeNewswire (Aug 7, 2012)
-
GlobeNewswire (Jul 30, 2012)
-
GlobeNewswire (Jul 24, 2012)
-
GlobeNewswire (Jul 20, 2012)
-
GlobeNewswire (Jul 19, 2012)
-
GlobeNewswire (Jul 17, 2012)
-
Business Wire (May 10, 2012)
-
Business Wire (Apr 30, 2012)
To learn more about Seeking Alpha Pro, click here.
-
Merck's Next-Gen Sleep Disorder Drug - A Blockbuster?Rx Stocks • Mon, Aug 27, 2012
-
Best Performing Russell 3,000 Stocks Year to DateBespoke Investment Group • Thu, Sep 2, 2010
-
Best and Worst Performing U.S. Stocks YTDBespoke Investment Group • Mon, Jul 26, 2010
-
Friday Options RecapFrederic Ruffy • Fri, Jul 2, 2010
-
Somaxon Pharmaceuticals, Inc. Q2 2008 Earnings Call TranscriptFri, Sep 5, 2008
-
Somaxon Pharmaceuticals Q4 2007 Earnings Call TranscriptThu, Apr 17, 2008
-
GlobeNewswire (Feb 5, 2013)
-
GlobeNewswire (Dec 17, 2012)
-
GlobeNewswire (Dec 11, 2012)
-
GlobeNewswire (Oct 31, 2012)
-
GlobeNewswire (Oct 22, 2012)
-
GlobeNewswire (Aug 27, 2012)
-
GlobeNewswire (Aug 7, 2012)
-
GlobeNewswire (Jul 30, 2012)
-
GlobeNewswire (Jul 24, 2012)
-
GlobeNewswire (Jul 20, 2012)
-
GlobeNewswire (Jul 19, 2012)
-
GlobeNewswire (Jul 17, 2012)
-
Business Wire (May 10, 2012)
-
Business Wire (Apr 30, 2012)
-
Business Wire (Apr 27, 2012)
-
Business Wire (Dec 19, 2011)
-
at MarketWatch.com (Nov 19, 2010)
-
at MarketWatch.com (Nov 19, 2010)
-
at MarketWatch.com (Aug 26, 2010)
SOMX vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. We submitted our NDA for Silenor®... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, February 5, 7:11 PM Somaxon Pharmaceuticals (SOMX) says it's entered into a settlement agreement with Actavis Elizabeth LLC and Actavis to resolve four patent litigation suits involving its Silenor 3 mg and 6 mg tablets. The settlement grants Somaxon an additional seven years protection on its patent, allowing Actavis the right to begin selling a generic version of Silenor on January 1, 2020, or earlier under certain circumstances. Shares +12% AH. Comment! [Healthcare]
- Monday, December 17, 2012, 4:51 PM Somaxon Pharmaceuticals (SOMX) says that its licensee Paladin Labs has received approval from Health Canada for its New Drug Submission for its insomnia treatment Silenor. The drug's launch is expected to around mid-2013. Shares +1% AH. Comment! [Healthcare, On the Move]
-
Tuesday, December 11, 2012, 12:45 PM
Midday top 10 gainers: BGMD +146%. SOMX +75%. ACUR +56%. TNS +43%. ULBI +18%. MEAD +16%. ESYS +15%. SZYM +14%. GTXI +13%. CLWR +12%.
Midday top 10 Losers: CBMX -11%. ESIO -11%. AMCN -9%. SEV -9%. GGAL -8%. SPW -8%. TELK -7%. [[JW-A]] -7%. MGLN -7%. SXC -7%. 2 Comments [On the Move] - Tuesday, December 11, 2012, 9:10 AM Somaxon Pharmaceuticals (SOMX) +103.4% premarket after agreeing to be acquired by Pernix Therapeutics (PTX) in a stock-for-stock transaction valued at $25M. Comment! [Healthcare, M&A, On the Move]
-
Tuesday, December 11, 2012, 9:10 AM
Premarket gainers: SOMX +101%. TNS +45%. VE +6%. CLDX +5%. URBN +5%.
Losers: ESIO -19%. Comment! [On the Move] - Monday, November 26, 2012, 12:45 PM Midday top 10 gainers: CBAK +80%. ENMD +23%. ANAD +19%. SSE +17%. HOGS +16%. SBLK +15%. CLSN +14%. SOMX +15%. GALT +14%. ACRX +12%. Midday top 10 Losers: SAB -14%. MMR -13%. CNIT -12%. CCCL -14%. BZ -9%. ZLC -9%. OXF -8%. MEIP -8%. PSTR -8%. AXX -7%. Comment!
- Friday, July 20, 2012, 10:38 AM Somaxon Pharmaceuticals (SOMX -19%) gets smacked after saying its selling approximately 9.4M shares of its common stock and warrants in a registered direct offering to purchase up to approximately 4.7M shares of its common stock to institutional investors at $0.32 per share and per warrant. Aggregate proceeds from the transaction will total approximately $3.0M. Comment! [Healthcare, On the Move]
- Wednesday, July 18, 2012, 11:43 AM Somaxon (SOMX +83%) soars this morning - after initially surging over 150% in pre-open trading - on the back of yesterday's announcement of its litigation settlement over Silenor with Mylan (MYL +0.8%) and Par Pharmaceuticals. The company added that it sees higher Q2 net sales for Silenor, now seeing revenue of approximately $2.8M to $2.9M, up from reported sales of $2.7M in Q1. Comment! [Healthcare, On the Move]
- Tuesday, July 17, 2012, 4:30 PM Somaxon Pharmaceuticals (SOMX) settles its patent litigation suit with Mylan (MYL) and Par Pharmaceutical (PRX) involving Silenor 3 mg and 6 mg tablets. The settlement grants MYL the exclusive right to begin selling a generic version of Silenor on January 1, 2020, and PRX the right to begin selling a generic version 180 days after a third party generic version is first sold in the U.S. under a license from Somaxon. Comment! [Healthcare]
- Monday, October 3, 2011, 4:50 PM Somaxon Pharmaceuticals (SOMX) jumps in post-trade after saying it had a productive meeting with the FDA relating to the over-the-counter development program for its insomnia drug Silenor, developed jointly with Procter & Gamble (PG). SOMX +22.5% AH. Comment! [Healthcare, On the Move]
-
Wednesday, February 23, 2011, 9:00 AM
Premarket gainers: VRTX +17%. OCLR +10%. CHS +5%. DTV +6%. CTIC +5%. SNV +4%. SOMX +4%.
Losers: SATC -14%. HPQ -9%. CNXT -6%. GRMN -6%. Comment! -
Tuesday, February 8, 2011, 9:00 AM
Premarket gainers: RHB +46%. KND +26%. CNXT +17%. XIDE +15%. SOMX +6%. CXZ +5%. CPST +5%. MT +5%. BYD +4%. MGM +4%. NTWK +4%. MOTR +4%. CCME +4%.
Losers: BR -12%. GLUU -7%. OLP -6%. TEVA -5%. RNN -5%. BBEP -5%. PPNT -5%. AVP -4%. KTOS -4%. Comment! -
Tuesday, November 30, 2010, 9:00 AM
Premarket gainers: BEZ +40%. KERX +9%. SOMX +6%. AEZS +4%.
Losers: CTIC -9%. ING -7%. IRE -7%. BBVA -5%. SDRL -5%. AIB -4%. STX -4%. DB -4%. BCS -4%. Comment! -
Tuesday, September 7, 2010, 9:00 AM
Premarket gainers: ORCL +8%. CASY +7%. RSCR +7%. ARNA +5%. SOMX +5%.
Losers: IDIX -51%. CSKI -26%. BCS -5%. IRE -5%. RTP -4%. ASML -4%. Comment! -
Wednesday, August 25, 2010, 9:20 AM
Premarket gainers: SOMX +28%. ACTG +7%.
Losers: AIB -7%. IRE -6%. Comment! - Wednesday, August 25, 2010, 8:03 AM Shares of Somaxon Pharmaceuticals (SOMX) are +31.2% premarket after the company announced a co-promotion pact with Procter & Gamble (PG) to market its insomnia drug, Silenor. PG -0.3%. (PR) Comment!